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Background: Tocilizumab is an effective therapy for patients with moderate to severe   rheumatoid 
arthritis that is administered by infusion over one hour every 4 weeks. The community-based 
infusion (ACTiv) program was introduced to Australia in August 2010 to provide accessible and 
convenient treatment for patients with rheumatoid arthritis who require tocilizumab. The primary 
objectives of this study were to determine the characteristics of patients in the ACTiv program, 
patient satisfaction, and patient-perceived benefits and concerns with the ACTiv program, and 
drivers of patient satisfaction and patient-perceived benefits and concerns.
Methods: A voluntary self-administered survey was given to all 608 patients in the ACTiv 
program between January 27, 2011 and March 31, 2011.
Results: A total of 351 surveys were returned completed, giving a response rate of 58% 
(351/608). Most patients in the ACTiv program were women aged 40–64 years, with a mean 
disease duration of 13.7 years and moderate disability, who had been in the ACTiv program 
for $5 months. Most patients (88%, 302/342) were either very satisfied or satisfied with the 
ACTiv program and believed that they were very unlikely or somewhat unlikely to switch 
from the ACTiv program (64%, 214/335). The most important benefit was the reassurance of 
receiving treatment from a trained nurse in a professional medical environment (33%, 102/309). 
The most important concern was the fear of side effects (48%, 134/280). The main drivers of 
patient satisfaction and patient-perceived benefits and concerns of patients were health profile, 
previous medication experience, and length of treatment time in the program.
Conclusion: The ACTiv program is used by patients of various ages, family life situations, 
and locations. Patient satisfaction with the program is high, which enables patients to benefit 
from long-term use of tocilizumab.
Keywords: arthritis, rheumatoid, infusions, intravenous, patient satisfaction, survey, health, 
tocilizumab
Introduction
Rheumatoid arthritis is a chronic inflammatory, autoimmune disorder that can lead to 
long-term joint damage. In Australia, about 400,000 people are affected by   rheumatoid 
arthritis.1 First-line therapy for patients with the disease usually involves at least 
one synthetic disease-modifying antirheumatic drug (DMARD), most commonly 
methotrexate,2 in combination with analgesics. However, synthetic DMARDs alone 
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are not effective in a considerable proportion of patients.3 
In patients with   moderate to severe rheumatoid arthritis, 
  biologic DMARDs (eg, abatacept, adalimumab, certoli-
zumab pegol, etanercept, golimumab, infliximab, rituximab, 
t  ocilizumab), which are administered by subcutaneous injec-
tion or intravenous infusion, may improve clinical outcomes 
and slow disease progression.4 In Australia, many rheuma-
tologists work in private practice and may not be affiliated 
with a hospital, hence biologic DMARDs that require regular 
intravenous infusion are often administered via community-
based5,6 or home-based7 infusion programs.
Tocilizumab is a humanized anti-interleukin-6   monoclonal 
antibody that is an effective monotherapy8 or combination 
therapy9 for patients with moderate to severe rheumatoid 
arthritis. Tocilizumab is prepared just before use and adminis-
tered by infusion over one hour every 4 weeks.10 In Australia, 
tocilizumab is administered by qualified and trained nurses 
in community-based infusion centers or in hospital settings. 
A community-based infusion (ACTiv) program sponsored by 
Roche Products Pty Limited (Dee Why, NSW, Australia) was 
introduced to Australia in August 2010 to provide accessible 
and convenient treatment for patients with rheumatoid arthri-
tis who require treatment with tocilizumab. Patients in the 
ACTiv program have access to a choice of infusion centers, 
are assigned a dedicated, trained infusion nurse who m  onitors 
each infusion, and can have their medication delivered to 
the infusion center. All patients eligible for treatment with 
tocilizumab are also eligible for the ACTiv program.
The primary objectives of this study were to determine 
the characteristics of patients in the ACTiv program, patient 
satisfaction and patient-perceived benefits and concerns with 
the ACTiv program, and the drivers of patient satisfaction 
and patient-perceived benefits and concerns. The secondary 
objective of the study was to assess decision-making in the 
treatment of rheumatoid arthritis.
Materials and methods
Study design
This survey was given to patients in the ACTiv program 
between January 27, 2011 and March 31, 2011. Ethics 
approval was obtained from the Bellberry human research 
ethics committee (Bellberry Limited, Dulwich, SA, 
  Australia) before the survey commenced. The survey was 
conducted in accordance with relevant guidelines and the 
code of Professional Behavior of the Australian Market and 
Social Research Society.
The survey was given to the patients along with   medication 
delivery, or given to the patients by a program nurse (if the 
patients did not have their medication delivered). However, 
it was not determined if the survey was delivered to all 
patients. The survey was voluntarily self-administered and 
patients were given the option to return an uncompleted 
survey. Uncompleted and completed surveys were sealed in 
an envelope and returned to the Pollinate research company 
(Surry Hills, NSW, Australia) by post.
Study population
All patients in the ACTiv program were invited to complete 
a survey (there were no exclusion criteria). All patients in 
the ACTiv program are adults ($18 years), have a diagnosis 
of moderate to severe rheumatoid arthritis, have previously 
had an incomplete response or no response to synthetic 
DMARDs, and are eligible for tocilizumab subsidized by 
the Australian pharmaceutical benefits scheme. The ACTiv 
program provides monthly administration of tocilizumab 
(Actemra®, Roche Products Pty Limited) by qualified and 
trained nurses in community-based infusion centers.
Survey information
The survey was designed by the author. Roche Products 
Pty Limited, Pollinate, and state infusion nurse managers 
provided input into the administration of the survey. The 
survey used lay terminology, was completed using written 
answers, and was anonymous. The survey was designed to 
be completed in less than 20 minutes.
The survey was provided as online supplementary data, 
and was divided into the following four parts: demographic 
profile, health profile, rheumatoid arthritis treatment history, 
and ACTiv program experience. Information on demographic 
profile and history of rheumatoid arthritis treatment was 
c  ollected using questions that requested information directly 
or selection of an answer(s). Health profile   information 
was c  ollected using the Stanford Health Assessment 
  Questionnaire-Disability Index (HAQ-DI),11 which has been 
validated in patients with rheumatoid arthritis.12 The HAQ-DI 
assesses a patient’s level of functional ability.13 The HAQ-DI 
is scored on a scale of 0 (no   disability) to 3 units (c  ompletely 
disabled). A HAQ-DI score of 0 to 1 indicates mild to moder-
ate   disability, a score of 1 to 2 indicates   moderate to severe 
disability, and a score of 2 to 3 indicates severe to very severe 
disability. Information on experience with the ACTiv program 
was collected using questions that requested information 
directly or questions that rated satisfaction (very dissatis-
fied, dissatisfied, neither satisfied or dissatisfied,   satisfied, 
very satisfied), likelihood (very unlikely, somewhat unlikely, 
neither unlikely nor likely, somewhat likely, very likely), and 
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relevancy (highly irrelevant, somewhat irrelevant, neutral, 
somewhat relevant, highly relevant).
Survey outcomes
The primary outcomes were demographics, health profile, 
treatment history, patient satisfaction, and patient benefits and 
concerns. The secondary outcome was decision-making.
Statistical analysis
To overcome any effect of the order of questions, the surveys 
were produced with responses in different orders. Batches of 
surveys were printed on different colored paper that indicated 
to the response coder which numeric code frame to use for 
data entry. A code book for all closed questions was created 
at the end of the survey and a code frame for all open ques-
tions was created after 80% of the surveys had been received. 
A single person entered the data from all surveys. The surveys 
were cross-checked to ensure that response scales have been 
interpreted in the correct direction. A completed survey was 
defined as a survey where at least 80% of the responses were 
valid and complete. A refusal was defined as the return of an 
uncompleted survey.
All data collection and statistical analyses were   conducted 
by Pollinate. Data were summarized using descriptive statis-
tics and were grouped by patient characteristics.   Differences 
between means were assessed using a t-test with a two-tailed 
α level of 0.05. Differences between proportions were 
assessed using a z-test with a two-tailed α level of 0.05. 
Missing data were not imputed for the analyses. All analy-
ses were conducted using IBM SPSS Statistics Version 19 
(New York, NY).
Results
At the end of the survey period there were 608 patients in 
the ACTiv program and 95 infusion centers staffed by 82 
qualified and trained nurses.
Survey response rate
A total of 351 surveys were returned completed, giving a 
response rate of 58% (351/608). In addition, 85 uncompleted 
and 15 partially completed surveys were returned. The 
remaining 157 surveys were not returned.
Demographic profile of patients
Patients in the ACTiv program represented a variety of ages, 
family life situations, and locations (Table 1). Because of the 
nature of the population, the demographics of the patients 
who did not return the survey could not be characterized.
Health profile of patients
The mean duration of rheumatoid arthritis for patients in 
the ACTiv program was 13.7 years (standard deviation 
10.3 years). Patients in the ACTiv program had moderate 
  disability (Tables 1 and 2) and most patients had mild or 
moderate overall HAQ-DI scores (Table 1). There was a 
significantly lower percentage of males (5%, 3/66) than 
females (20%, 55/276) with a severe overall HAQ-DI score 
(P , 0.05). The relative disability of patients in the ACTiv 
program was influenced by many demographic   characteristics 
(Table 2).
history of rheumatoid arthritis treatment
Sixty-five percent (212/328) of patients had been in the 
ACTiv program for $5 months. The remaining patients 
(35%, 116/328) had been in the program for 1–4 months 
(note, patients must demonstrate a response to treatment, 
based on assessment after about 3 months of treatment, in 
order to continue government-funded treatment).
Most patients had been treated previously with one or 
more biologic DMARDs, although 20% (71/351) of patients 
had not been treated previously with a biologic DMARD 
for rheumatoid arthritis (Table 1). About half of the patients 
had been treated previously with a subcutaneous biologic 
DMARD and some had been treated previously with an 
intravenous DMARD (Table 1).
Patients typically received concomitant treatment for 
rheumatoid arthritis while they were in the ACTiv program. 
The most common concomitant rheumatoid arthritis treat-
ment was synthetic DMARDS, taken by 66% (232/351) 
of patients and the most common synthetic DMARD was 
methotrexate, taken by 56% (197/351) of patients. A small 
percentage (13%, 46/351) of patients took tocilizumab with-
out additional synthetic DMARDs, steroids, or nonsteroidal 
anti-inflammatory drugs.
Patients who had been in the ACTiv program for 
$5 months took significantly less concomitant rheumatoid 
arthritis treatment than patients who had been in the ACTiv 
program for 1–4 months. Fewer patients who had been in the 
ACTiv program for $5 months took synthetic DMARDs 
(61% [130/212] versus 77% [89/116], P , 0.05), in particular 
methotrexate (51% [108/212] versus 67% [78/116], P , 0.05), 
compared with patients who had been in the program for 
1–4 months. Significantly more patients who had been in the 
ACTiv program for $5 months did not use concomitant syn-
thetic DMARDs, steroids, or nonsteroidal anti-inflammatory 
drugs, compared with patients who had been in the program for 
1–4 months (15% [32/212] versus 7% [8/116], P , 0.05).
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Table 1 Demographic and health profile of patients in the community-based infusion program
Characteristic Total 
N = 351
Female 
n = 282
Male 
n = 66
Mean age, years (SD) 55.4 (13.7) 54.9 (14.2) 57.8 (11.3)
18–39 years, % (n) 11 (39) 14 (38) 1.5 (1)*
40–64 years, % (n) 60 (210) 58 (162) 71 (47)*
65+ years, % (n) 28 (99) 29 (81) 27 (18)
Partner status, % (n)
Does not live with partner 39 (135) 40 (112) 33 (22)
Lives with partner 61 (212) 60 (168) 67 (44)
Highest level of education, % (n)
Year 9 or below 16 (55) 14 (40) 23 (15)
Year 10 19 (67) 21 (58) 14 (9)
Year 11 or 12 17 (58) 17 (47) 17 (11)
Diploma or certificate from a college or TAFE 28 (97) 27 (75) 32 (21)
Degree or diploma from a university 16 (56) 16 (46) 15 (10)
Postgraduate degree 4 (14) 5 (14) 0 (0)
Employment status, % (n)
Works part-time or full-time 36 (126) 34 (96) 46 (30)
Does not work, 18–39 years 37 (129) 39 (108) 30 (20)
Does not work, 65+ years 26 (91) 27 (75) 24 (16)
Household annual income before tax, % (n)
Under $20,000 8 (28) 8 (23) 8 (5)
$20,000–$49,999 19 (64) 17 (47) 24 (16)
$50,000–$79,999 16 (55) 16 (46) 14 (9)
$80,000–$99,999 6 (20) 6 (16) 6 (4)
$100,000–$149,999 6 (21) 6 (18) 5 (3)
$150,000 or more 4 (15) 4 (12) 5 (3)
Social security benefit/pension 20 (70) 20 (56) 20 (13)
I don’t know/I don’t wish to divulge 22 (78) 22 (64) 20 (13)
Location, % (n)
State capital city, ,20 km from CBD 23 (78) 25 (69) 14 (9)
State capital city, .20 km from CBD 19 (67) 18 (51) 24 (16)
regional center or large town 36 (125) 36 (100) 36 (24)
rural area 22 (76) 21 (58) 26 (17)
Median distance, km (min, max)
From infusion center 10 (0, 300) 10 (0, 300) 10 (1, 150)
From nearest hospital 10 (0, 70) 10 (0, 60) 10 (1, 70)
Treatment history with biologic DMARDs, % (n)
no biologics previously used 20 (71) 20 (57) 20 (13)
Used 1 biologic before tocilizumab 32 (111) 31 (87) 35 (23)
Used 2 biologics before tocilizumab 27 (94) 26 (73) 32 (21)
Used 3 or more biologics before tocilizumab 21 (75) 23 (65) 14 (9)
Treatment administration history, % (n)
no iV or SC treatment 20 (71) 20 (57) 20 (13)
Used iV only or iV and SC treatment 28 (100) 30 (86) 20 (13)
Used SC treatment only 51 (180) 49 (139) 61 (40)
Time in the ACTiv program, % (n)
1 to 4 months 35 (116) 36 (95) 35 (21)
5 or more months 65 (212) 64 (170) 65 (39)
Overall adjusted HAQ-DI scorea, mean (SD) 1.2 (0.7) 1.3 (0.7) 1.0 (0.7)
Mild score (hAQ-Di 0 to 1), % (n) 36 (124) 34 (94) 44 (29)
Moderate score (hAQ-Di 1 to 2), % (n) 47 (163) 46 (127) 52 (34)
Severe score (hAQ-Di 2 to 3), % (n) 17 (58) 20 (55) 5 (3)*
Ability to carry out everyday activities scoreb, mean (SD) 2.4 (1.0) 2.4 (1.0) 2.1 (1.0)*
Pain score in the past weekc, median (min, max) 45 (0, 100) 50 (0, 100) 30 (0, 100)
Health score in the last weekc, median (min, max) 50 (0, 100) 50 (0, 100) 50 (0, 100)
Notes: *P , 0.05 compared with females; ascore range of 1 to 3; bscore range of 1 to 5; cscore out of 100.
Abbreviations: CBD, central business district; DMArD, disease-modifying antirheumatic drug; hAQ-Di, health assessment questionnaire – disability index; iV, intravenous; 
max, maximum; min, minimum; SC, subcutaneous; SD, standard deviation.
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Some patients discontinued rheumatoid arthritis treat-
ment after being in the ACTiv program. Discontinuation 
of concomitant rheumatoid arthritis treatment was higher 
for patients who had been in the ACTiv program for longer. 
For example, synthetic DMARD use was discontinued 
by 44% (93/212) of patients who had been in the pro-
gram for $5 months compared with 25% (29/116) of patients 
who had been in the program for 1–4 months (P , 0.05).
Patient satisfaction with program
Overall, most patients (88%, 302/342) were either very 
satisfied or satisfied with the ACTiv program. Only 1.2% 
(4/342) of patients were dissatisfied with the ACTiv program. 
Gender, age, partner status, employment status, decision-
making views, and treatment history did not influence patient 
satisfaction with the ACTiv program. Significantly more 
patients in the ACTiv program for $5 months were very 
satisfied or satisfied with the program compared with patients 
in the program for 1–4 months (91% [193/211] versus 81% 
[88/108], P , 0.05). Patients with a low overall HAQ-DI 
score were significantly more likely to be very satisfied or 
satisfied with the ACTiv program than patients with medium 
or high overall HAQ-DI scores (96% [118/123] versus 83% 
[131/157] and 86% [49/57] respectively, P , 0.05).
Patients generally believed that they were very unlikely 
or somewhat unlikely to switch from the ACTiv program 
(64%, 214/335). Only 9% (31/335) of patients believed that 
they were somewhat likely or very likely to switch from the 
ACTiv program. The likelihood of patients switching from the 
ACTiv program was influenced by the duration the patients had 
been in the program (1–4 months, 49% [52/106]; $5 months, 
70% [144/206], P , 0.05), treatment history with biologic 
DMARDs (for patients previously treated with at least three 
biologic DMARDs 59% [42/71] were very unlikely or some-
what unlikely to switch compared with 79% [53/67] of patients 
who had not previously received any biologic   treatment, 
P , 0.05), and overall HAQ-DI score (for patients with a low 
HAQ-DI score 77% [92/120] were very unlikely or somewhat 
unlikely to switch compared with 55% [84/154] of patients 
with a medium HAQ-DI score, P , 0.05).
Benefits and concerns perceived  
by patients
The most important benefit of the ACTiv program that 
was most frequently selected was reassurance of receiving 
t  reatment from a trained nurse in a professional medical 
environment (benefit 1, 33% [102/309] of patients, Table 3). 
Other highly rated benefits included no need to self-adminis-
ter injections (benefit 2), overall convenience (benefit 3), and 
the fact that Actemra is a newer agent compared with some 
of the alternatives (benefit 4). Demographic and health fac-
tors (gender, age, employment status, duration on program, 
history of biologic DMARD treatment, overall HAQ-DI 
score, administration method, partner status, location) did 
not influence patient selection of the most important benefits 
of the ACTiv program.
Table 2 Health profile of patients (by group) in the community-based infusion program
Patient group Mean RA period  
(years)
Mean overall HAQ-DI  
scorea
Ability to carry out everyday   
activitiesb
Total 13.7 1.2 2.4
Female 14.1 1.3 2.4
Male 11.6 1.0* 2.1*
18–39 years 11.2 1.1 2.0
40–64 years 13.2 1.2 2.3
$65 years 15.7 1.3 2.6†
Does not live with partner 14.2 1.3 2.4
Lives with partner 13.4 1.2 2.3
Works 11.7‡ 0.8‡ 1.9‡
Does not work, 18–64 years 14.2 1.4 2.6
Does not work, $65 years 15.5 1.3 2.6
ACTiv program 1–4 months 12.0 1.3 2.4
ACTiv program $5 months 14.1 1.2 2.3
no biologics 12.3 0.9 2.1
Used 1 biologic 13.3 1.2 2.4
Used 2 biologics 13.9 1.3§ 2.5
Used 3 or more biologics 15.4 1.4§ 2.5
Notes: *P , 0.05 compared with females; †P , 0.05 compared with younger age groups; ‡P , 0.05 compared with does not work groups; §P , 0.05 compared with no 
biologics; ascore range of 1 to 3; bscore range of 1 to 5.
Abbreviations: ACTiv, community-based infusion; hAQ-Di, health Assessment Questionnaire-Disability index; rA, rheumatoid arthritis.
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All benefits were considered to be relevant to the patient’s 
own experience with the ACTiv program (Table 3, relevance 
scores). However, patients’ perceptions of relevance varied 
with demographic and health factors. Patients who had 
been in the program for longer considered regular contact 
with a nurse (benefit 6, Table 3) to be more relevant than 
patients who had been in the program for a shorter period 
(mean relevance score 4.1 versus 4.4, P , 0.05). In addition, 
patients who had not previously used a biologic DMARD 
considered that the reassurance of receiving treatment from 
a trained nurse in a professional environment (benefit 1), 
regular contact with a nurse (benefit 6), no need to pick up 
prescriptions or prepare drugs (benefit 7), and the appeal of 
an infusion center environment (benefit 8) to be more   relevant 
than patients who had used intravenous or intravenous and 
subcutaneous biologic DMARDs, respectively (mean rel-
evance scores 4.8, 4.5, 4.6, and 4.2 versus 4.4, 4.1, 4.1, and 
3.5, respectively, P , 0.05).
The most important concern with the ACTiv program 
that was most frequently selected was the fear of side effects 
(concern 1, 48% [134/280] of patients, Table 4). Overall, the 
concerns noted in the survey were considered by patients 
to be less relevant to their own experience with the ACTiv 
program compared with the benefits (relevance scores 
Table 4 versus Table 3). Some demographic and health fac-
tors (duration on program, overall HAQ-DI score, location) 
appeared to influence the selection of the most important 
concerns with the ACTiv program. The factors considered 
Table 4 Patient-perceived concerns with the community-based infusion program that were selected as most important
Concern with the ACTiv program % (n) Patientsa 
n = 280
Mean relevance   
scoreb (SD)
  1.  Fear of side effects 48 (134) 3.2 (1.3)
  2.  Distance from nearest infusion center 9 (25) 2.6 (1.5)
  3.  Actemra is a newer agent compared to some other alternativesc 8 (22) 2.7 (1.3)
  4.  Total treatment time of 1.5–2 hours substantially longer than some alternatives 7 (20) 2.4 (1.2)
  5.  Loss of flexibility and independence associated with self-injecting 7 (20) 2.4 (1.4)
  6.  inconvenience of travelling to and from the infusion center 6 (16) 2.4 (1.4)
  7.  Anxiety about the infusion procedure 4 (10) 2.2 (1.2)
  8.  More frequent treatments 3 (9) 2.2 (1.2)
  9.    Lower appeal of infusion center environment compared with alternatives such as hospital  
or specialist’s offices
3 (9) 2.3 (1.3)
10.  Lower reassurance due to lack of doctor or specialist at treatment 3 (8) 2.0 (1.1)
11.  Overall inconvenience 2 (5) 2.4 (1.3)
12.  Feel less in control of treatment 1 (4) 2.1 (1.1)
Notes: aPercentage of patients who selected this benefit as the single top concern with the program; bpatients were asked for the relevance of the possible concerns to their 
own experience with the ACTiv program. Score range from 1 (highly irrelevant) to 5 highly relevant; cActemra is the brand name of tocilizumab.
Abbreviations: SD, standard deviation; ACTiv, community-based infusion.
Table 3 Patient-perceived benefits of the community-based infusion program that were selected as most important
Benefit of the ACTiv program % (n) Patientsa 
n = 309
Mean relevance   
scoreb (SD)
  1.    reassurance of receiving treatment from trained nurse in a professional  
medical environment
33 (102) 4.6 (0.9)
  2.  No need to self-administer injections 20 (62) 4.0 (1.3)
  3.  Overall convenience 9 (29) 4.2 (1.1)
  4.  Actemrac is a newer agent compared with some other alternatives 9 (29) 3.7 (1.2)
  5.  Proximity of infusion center 8 (24) 4.1 (1.2)
  6.  regular contact with nurse 5 (14) 4.3 (1.0)
  7.  no need to pick up prescriptions or prepare drugs 5 (14) 4.3 (1.1)
  8.    Appeal of infusion center environment compared to alternatives such as hospital  
or specialist’s office
4 (11) 3.9 (1.3)
  9.  Frequency of visits 4 (11) 4.0 (1.2)
10.  Opportunity to meet up with other rA patients at the infusion center 1 (4) 2.8 (1.3)
11.  infusion time spent relaxing, eg, catching up on magazines 0 (1) 3.4 (1.3)
Notes: aPercentage of patients who selected this benefit as the single top benefit of the program; bpatients were asked for the relevance of the possible benefits to their own 
experience with the ACTiv program. Score range from 1 (highly irrelevant) to 5 (highly relevant); cActemra is the brand name of tocilizumab.
Abbreviations: rA, rheumatoid arthritis; SD, standard deviation; ACTiv, community-based infusion.
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to be of most concern in patients who had been in the ACTiv 
program for a shorter period compared with a longer period 
were Actemra being a newer agent (concern 3: 1–4 months, 
13% [12/92] versus $ 5 months, 5% [9/168], P , 0.05) and 
lower reassurance due to the lack of a doctor or specialist 
being present during treatment (concern 10: 1–4 months, 5% 
[5/92] versus $ 5 months, 1% [2/168], P , 0.05). In addition, 
anxiety about the infusion procedure was of more concern 
for patients with a high overall HAQ-DI score compared 
with patients with a medium score (concern 7: 12% [5/42] 
versus 1% [1/123], P , 0.05). Distance from the nearest 
infusion center was of most concern to patients from a rural 
area (concern 2: 20% [11/56]).
The most common answers when patients were asked 
“what would you say to other rheumatoid arthritis patients 
about the ACTiv program” were “good staff/service” (by 
40% [122/306] of patients), “convenient and easy” (by 33% 
[100/306] of patients), and “satisfied/happy” (good/great/
excellent, by 24% [72/305] of patients).
Decision-making about treatment
Overall, most patients (77%, 264/344) thought that the final 
decision about treatment for their rheumatoid arthritis should 
be a joint decision between the patient and their rheumatolo-
gist, rather than by their rheumatologist alone (18%, 61/344) 
or the patient alone (5%, 19/347). The patients’ thoughts about 
who should make the final decision regarding treatment of 
rheumatoid arthritis was influenced by gender, age, employ-
ment status, and previous rheumatoid arthritis treatment 
administration method. Patients who reported that the final 
decision about their treatment for rheumatoid arthritis should 
be made by the rheumatologist were mostly male (males ver-
sus females: 27% [17/64] versus 16% [44/280], P , 0.05), 
older (65 years versus 40–64 years: 28% [27/98] versus 14% 
[29/207], P , 0.05), and did not work (older patients who did 
not work versus worked: 28% [25/91] versus 13% [16/126], 
P , 0.05) Patients who reported that the final decision about 
their rheumatoid arthritis treatment should be a joint decision 
between the patient and their rheumatologist were mostly 
female (female versus male: 80% [225/282] versus 64% 
[42/66], P , 0.05) and those who had previously used subcu-
taneous biologic DMARDs (previous use versus no previous 
use: 80% [144/180] versus 66% [47/71], P , 0.05).
The final decision to join the ACTiv program was 
mostly (66% [230/348] of patients) made as a joint decision 
between the patient and their rheumatologist, rather than by 
their rheumatologist alone (30%, 104/348) or the patient 
alone (4%, 14/348). The older the patient, the more likely it 
was that the rheumatologist made the decision to enter the 
ACTiv program (18–39 years, 8% [3/39]; 40–64 years, 28% 
[58/207]; 65+ years, 43% [43/99]).
Discussion
Understanding the characteristics of patients and their beliefs 
is advantageous to rheumatologists when making decisions 
about treatment of rheumatoid arthritis. This is the first study 
to investigate patient characteristics, patient satisfaction, 
drivers of patient satisfaction, and patient-perceived benefits 
and concerns in a community-based infusion program for 
delivery of a biologic DMARD to patients with rheumatoid 
arthritis. Overall, this study found that patients in the ACTiv 
program for tocilizumab in Australia were very satisfied 
with the program; reassurance of receiving treatment from 
a trained nurse was the most frequently reported important 
benefit of the program and, to a lesser extent, fear of side 
effects was the most frequently reported important concern. 
The main drivers of patient satisfaction and patient-perceived 
benefits and concerns identified were health profile, previous 
medication experience, and length of treatment time in the 
ACTiv program.
Although the patients in the ACTiv program represented 
a wide range of patients, in general, most were women aged 
from 40–64 years with a mean disease duration of 13.7 years 
and moderate disability. In addition, most patients had 
received treatment with a biologic DMARD before receiving 
tocilizumab. This demographic profile reflects the general 
population of patients with rheumatoid arthritis treated 
with biologic DMARDs and is consistent with the profile 
of patients with rheumatoid arthritis who are registered for 
tocilizumab treatment in Europe.14 Although the demographic 
characteristics of patients in the ACTiv program were not 
found to be drivers of patient satisfaction or patient-perceived 
benefits and concerns, they did influence patients’ perceptions 
of decision-making about their treatment. In general, most 
patients in the ACTiv program were involved, with their 
rheumatologist, in decision-making about their treatment. 
This finding is in contrast with a British study of patients 
with rheumatoid arthritis taking antitumor necrosis factor-α 
therapy, which found that only 7% of patients were jointly 
involved with their rheumatologist in decision-making about 
the treatment of their rheumatoid arthritis.15 The differences 
in treatment decision-making between the current study and 
the British study may reflect differences in the study popula-
tion, socioeconomic factors, or culture.
The most important benefit of the ACTiv program 
that was identified most frequently in this study was the 
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  reassurance patients gained from receiving treatment from 
a trained nurse in a professional medical environment. This 
is similar to an Italian study of patients with rheumatoid 
arthritis on antitumor necrosis factor-α therapy,16 which high-
lights the importance of direct interaction between patients 
and   professionals. Other benefits included no need to self-
administer injections, overall convenience, and the newness 
of Actemra compared with alternative treatments. Although 
some benefits were considered to be more relevant (reassur-
ance of receiving treatment from a trained nurse in a profes-
sional environment, regular contact with a nurse, no need to 
pick up prescriptions or prepare drugs, and the appeal of an 
infusion center environment) than others by patients who 
had been in the program for longer or who had previously 
received treatment with a biologic DMARD, no demographic 
or health factors were identified that influenced patients’ 
selection of the important benefits of the program.
In contrast with the perceived benefits of the ACTiv 
program, the level of concern among patients in the program 
was relatively low, with important concerns being rated less 
relevant than important benefits. As would be expected, the 
most common concern of patients in the program was fear 
of side effects. Patients receive information regarding the 
potential side effects of their treatment from their doctors, 
their previous experience with other medications, and from 
other sources (eg, social groups, Internet sites). Hence, this 
finding highlights the importance of counseling patients about 
how to avoid side effects and what patients should do if side 
effects occur. The factors that appeared to drive patients’ 
concerns were the duration of time in the ACTiv program, 
severity of disability (HAQ-DI), and living distance from the 
infusion center. More patients who had been in the ACTiv 
program for a shorter period of time rated the newness of 
Actemra and the lower reassurance due to the lack of a doctor 
or specialist at treatment as important concerns, more patients 
with greater disability rated anxiety about the infusion proce-
dure as an important concern, and more patients from rural 
areas rated their living distance from the infusion center as 
an important concern. These findings further highlight the 
role of the trained nurse in the ACTiv program in providing 
the appropriate counseling and reassurance required with 
regard to any potential effects of treatment or the infusion 
procedure, and will assist rheumatologists when counseling 
patients with regard to their treatment options.
An important finding from this study was that increased 
access to tocilizumab through the ACTiv program enabled 
patients to achieve the benefits of long-term treatment with 
tocilizumab. Patients who had been in the ACTiv program 
for $5 months used less concomitant rheumatoid arthritis 
medication and had a higher rate of discontinuation of 
concomitant rheumatoid arthritis medication. In particular, 
discontinuation of concomitant steroid use was high in 
patients who had been in the ACTiv program for longer 
(26% rate of discontinuation), which is consistent with the 
findings from a long-term study of tocilizumab treatment in 
patients with rheumatoid arthritis from Japan (32% rate of 
discontinuation).17 In addition to the benefits of long-term 
treatment, the length of time that a patient had been in the 
ACTiv program was a driver of patient satisfaction. This 
may in part be because patients who were in the program 
for longer experienced an improvement in health (data not 
presented) and, as described earlier, because of the influ-
ence of duration of time in the program on patient-perceived 
benefits and concerns.
The strength of the survey is that the results are directly 
relevant for the rheumatologists in Australia who are caring 
for patients with rheumatoid arthritis and will assist in deci-
sion-making and counseling of patients with regard to their 
treatment options. Given the success of community-based 
infusion programs, there may be a move to more community-
based care for patients with rheumatoid   arthritis.18 Hence, 
the findings in this study may be applicable to infusion 
programs underway for other biologic DMARDs or other 
drugs. The survey had a response rate of 58%, which meets 
the expectations of surveys in general19 and patients were 
representative of those with rheumatoid arthritis who receive 
treatment with biologic DMARDs. However, because not 
all patients responded to the survey, it is possible that the 
results are not representative of all patients in the ACTiv 
program. In addition, when applying the findings of this 
study to clinical practice, clinicians should consider that 
the survey was not validated in pretesting analysis, did not 
measure clinical outcomes, and did not compare the ACTiv 
program with other methods of tocilizumab infusion or other 
biologic DMARDs.
In conclusion, the ACTiv program in Australia is used 
by patients of various ages, family life situations, and   locations. 
Patient satisfaction with the program is high and enables 
patients to benefit from long-term treatment with tocilizumab. 
The most important perceived benefit of the program was 
the reassurance patients gain from receiving treatment from 
a trained nurse in a professional medical   environment. Other 
important benefits included overall convenience and removal 
of the need to self-administer   injections. Although perceived 
concerns about the program were rated less relevant than 
benefits, the most common   concern was a fear of side effects. 
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This study suggests that factors such as health profile,   previous 
medication experience, and length of time on treatment, rather 
than demographic or decision-making factors, may be driv-
ers of patient satisfaction and patient-perceived benefits and 
concerns with the ACTiv program.
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